

The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
Nov 6, 2024
Marina Konopleva is the Director of Leukemia at Montefiore Cancer Center, while Emma Groarke is an Associate Research Physician at the NIH. They delve into the landscape of rare myeloid diseases like BPDCN, CMML, and VEXAS, discussing innovative therapies including Tagrexofaspa and IDH inhibitors. The conversation highlights the complexities in treatment due to patient variability and the significance of risk stratification in decision-making. They also emphasize the importance of collaborative research to enhance outcomes in these challenging conditions.
Chapters
Transcript
Episode notes
1 2 3 4 5
Intro
00:00 • 2min
Advancements in BPDCN Treatment and Future Directions
02:10 • 3min
Novel Therapeutics and Challenges in Chronic Myelomonocytic Leukemia
04:54 • 2min
Understanding VEXAS and its Therapeutic Challenges
07:03 • 13min
Advancements and Strategies in Treating BPDCN and MPNs
19:52 • 3min